No interaction studies have been performed with Rebif (interferon β-1a) in humans. Interferons have been reported to reduce the activity of hepatic cytochrome P-450-dependent enzymes in humans and animals. Caution should be exercised when administering Rebif in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P-450 system for clearance eg, antiepileptics and some classes of antidepressants.
The interaction of Rebif with corticosteroids or ACTH has not been studied systematically. Clinical studies indicate that multiple sclerosis patients can receive Rebif and corticosteroids or ACTH during relapses.
Incompatibilities: Not applicable.